Artrite idiopatica giovanile

Bibliogra!a 1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369(9563):767. 2. Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first step, Pediatric Rheumatology International trial Organization Consensus. J Rheumatol 2018;46(2):190-7. 3. Ombrello MJ, Arthur VL, Remmers EF, et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis 2017;76(5):906-13. 4. Stock CJ, Ogilvie EM, Samuel JM, Fife M, Lewis CM, Woo P. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes and Immunity 2008;9:349-57. 5. Pardeo M, Pires Marafon D, Insalaco A, et al. Anakinra in systemic juvenile idiopathic arthritis: a single Center experience. J Rheumatol 2015;42(8):1523-7. 6. De Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 2005;52:687-93. 7. De Benedetti F. Tocilizumab for systemic juvenile idiopathic arthritis. N Engl J Med 2013;368(13):1256-7. 8. Jing Yao L, Guan Y G, Albani S, Arkachaisri T. Recent advances in our understanding of the pathogenesis of juvenile idiopathic arthritis and their potential clinical implications. Expert Review of Clinical Immunology 2018;14(11)933-44. 9. Hinks A, Cobb J, Marion MC, et al. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet 2013; 45:664. 10. Prahalad S, Glass DN. A comprehensive review of the genetic of juvenile idiopathic arthritis. J Pediatr Rheumatol Online 2008;6: 11. 11. Spreafico R, Rossetti M, van Loosdregt J, et al. A circulating reservoir of pathogeniclikeCD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial microenvironment. Ann Rheum Dis 2016;75 (2):459-65. 12. Rossetti M, Spreafico R, Consolaro A, et al. TCR repertoire sequencing identifies synovial T-reg cell clonotypes in the bloodstream during active inflammation in human arthritis. Ann Rheum Dis 2017;76(2):435-41. 13. Kamada N, Su S, Gy C, et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013;13:321. 14. Verwoerd A, Ter Haar NM, de Roock S, et al. The human microbiome and juvenile idiopathic arthritis. Pediatric Rheumatol 2016;14:55. 15. Nistala K, Moncrieffe H, Newton KR, et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell number. Arthritis Rheum 2008;58: 875. 16. Basra HAS, Humpries PD. Juvenile idiopathic arthritis: what is the utility of ultrasound? Br J Radiol 2017;90(1073):20160920. 17. Malattia C, Rinaldi M, Martini A. The role of imaging in juvenile idiopathic arthritis. Expert Rev Clin Immunol 2018;14(8):681-94. 18. Malattia C, Tzaribachev N, van den Berg JM, Magni-Manzoni S. Juvenile idiopathic arthritis - the role of imaging from rheumatologist’s perspective Pediatr Radiol 2018;48 (6):785-91. 19. Rebollo-Polo M, Koujok K, Weisser C. Ultrasound findings on patients with juvenile idiopathic arthritis in clinical remission. Arthritis Care Res (Hoboken) 2011;63(7):1013-9. 20. Magni-Manzoni S, Scirè CA, Ravelli A, et al. Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. Ann Rheum Dis 2013;72(2):223- 8. 21. Zulian F, Martini G, Gobber D, et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology 2003;42(10):1254. 22. Padeh S, Passwell JH. Intraarticular corticosteroid injections in the management of children with chronic arthritis. Arthritis Rheum 1998;41:1210. 23. Lepore L, Del Santo M, Malorgio C, et al. Treatment of juvenile idiopathic arthritis with intra-articular triamcinolone hexacetonide: evaluation of clinical effectiveness correlated with circulating ANA and T gamma/delta + and B CD5+ lymphocyte populations of synovial fluid. Clin Exp Rheumatol 2002;20(5): 719. 24. Uziel Y, Chapnick G, Rothschild M, et al. Nitrous Oxide sedation for intra-articular injection in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2008;15:6. 25. Ruperto N, Murray KJ, Gerloni V, et al.; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004 ;50(7):2191-201. 26. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303(13):1266-73. 27. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342(11):763-9. 28. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58(5):1496. 29. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26(4):688. 30. Horneff G, De Bock F, Foeldvari I, et al. German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68(4):519-25. 31. Ruperto N, Lovell DJ, Cuttica R, et al. Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69(4): 718-22. 32. Ruperto N, Lovell DJ, Cuttica R, et al. Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo- controlled trial of infliximab plus methotrexate for the treatment of polyarticularcourse juvenile rheumatoid arthritis. Arthritis Rheum 2007;56(9):3096-106. 33. Lovell DJ, Ruperto N, Goodman S, et al. Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359(8):810-20. 34. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhoodrefractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthr Care Res (Hoboken) 2011;63(4): 612. 35. Lovell DJ , Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol 2015;67 (10):2759-70. 36. Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first- line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. J Rheumatol 2016;43(11):2068-73. 37. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2385. 38. Brunner HI, Ruperto N, Zuber Z, et al; Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015;74(6):1110-7. 39. Pastore S, Naviglio S, Canuto A, Lepore L, et al. Serious adverse events associated with anti-tumor necrosis factor alpha agents in pediatric-onset inflammatory bowel disease and juvenile idiopathic arthritis in a real-life setting. Paediatr Drugs 2018;20(2):165- 171. 40. Furst DE, Keystone EC, So A, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72:ii2-34. 41. Lahdenne P, Wikström AM, Aalto K, Kolho KL. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthr Care Res (Hoboken) 2010;62:785-90. 42. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005;11:442. 43. Pastore S, Londero M, Gortani G, et al. Infliximab-related vasculitis in patients affected by ulcerative colitis. J Pediatr Gastroenterol Nutr 2010;51:226. 44. Lepore L, Marchetti F, Facchini S. Druginduced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003;21(2):276. 45. Oikonomou KA, Kapsoritakis AN, Tsiopoulos FD, et al. Emergence of Crohn’s disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence? J Gastrointestin Liver Dis 2010;19:342. 46. McCroskery P, Wallace CA, Lovell DJ, et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010;8:18. 47. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024. 48. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704. 49. Felis-Giemza A, Chmurzyńska K, Nałęcz- Janik J. Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. Reumatologia 2019;57(5):257-63. 50. Simonini G, Ferrara G, Pontikaki I, et al. Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration. Arthr Care Res 2018;70(7):1046-51. 51. Aquilani A, Marafon DP, Marasco E, et al. Predictors of flare following etanercept withdrawal in patients with rheumatoid factor-negative juvenile idiopathic arthritis who reached remission while taking medication. J Rheumatol 2018;45(7):956-61. 52. Horton DB, Onel KB, Beukelman T, Ringold S. Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the Childhood Arthritis and Rheumatology Research Alliance. J Rheumatol 2017;44(3):352- 360. 53. Ruperto N, Brunner HI, Zuber Z et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J 2017;15:86. 54. Kremer JM, Emery P, Camp HS, et al. A Phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthr Rheumatol 2016;68(12):2867-77. 55. Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018;77(6):819-28. 56. Consolaro A Giancane G, Schiappapietra B, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2016;14(1):23.